Agios Pharmaceuticals (AGIO) Net Cash Flow (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Net Cash Flow for 15 consecutive years, with $24.5 million as the latest value for Q1 2026.

  • For Q1 2026, Net Cash Flow rose 800.63% year-over-year to $24.5 million; the TTM value through Mar 2026 reached $34.6 million, up 187.03%, while the annual FY2025 figure was $12.9 million, 207.74% up from the prior year.
  • Net Cash Flow hit $24.5 million in Q1 2026 for Agios Pharmaceuticals, up from -$3.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $169.2 million in Q3 2024 and bottomed at -$177.5 million in Q4 2024.
  • Average Net Cash Flow over 5 years is -$5.3 million, with a median of $2.7 million recorded in 2025.
  • Year-over-year, Net Cash Flow tumbled 941.1% in 2022 and then surged 928.66% in 2024.
  • Agios Pharmaceuticals' Net Cash Flow stood at $16.8 million in 2022, then soared by 42.01% to $23.9 million in 2023, then plummeted by 843.48% to -$177.5 million in 2024, then surged by 97.98% to -$3.6 million in 2025, then soared by 783.52% to $24.5 million in 2026.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at $24.5 million, -$3.6 million, and $11.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.